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A B S T R A C T
Nitric oxide (NO) donors are commonly used for the prevention and treatment of ischemic heart disease. Besides their effects on the heart, NO donors may also
prevent hypoxic brain damage and exert beneficial effects on atherosclerosis by favoring features of plaque stability. We recently described that apolipoprotein E
(ApoE) deficient mice with a mutation in the fibrillin-1 (Fbn1) gene (ApoE-/-Fbn1C1039G+/-) develop accelerated atherosclerosis, plaque rupture, myocardial infarction,
cerebral hypoxia and sudden death. In the present study, we evaluated the effects of chronic treatment with the NO donor molsidomine on atherosclerotic plaque
stability, cardiac function, neurological symptoms and survival in the ApoE-/-Fbn1C1039G+/- mouse model. Female ApoE-/-Fbn1C1039G+/- mice were fed a Western diet
(WD). After 8 weeks of WD, the mice were divided into two groups receiving either molsidomine via the drinking water (1mg/kg/day; n= 34) or tap water (control;
n= 36) until 25 weeks of WD. Survival tended to increase after molsidomine treatment (68% vs. 58% in controls). Importantly, atherosclerotic plaques of molsi-
domine-treated mice had a thicker fibrous cap (11.1 ± 1.2 vs. 8.1 ± 0.7 μm) and showed an increased occurrence of plaque macrocalcifications (30% vs. 0%),
indicative of a more stable phenotype. Molsidomine also improved cardiac function, as fractional shortening was increased (40 ± 2% vs. 27 ± 2%) combined with
a decreased end diastolic (3.1 ± 0.2 vs. 3.9 ± 0.2mm) and end systolic diameter (1.9 ± 0.1 vs. 2.9 ± 0.2mm). Furthermore, perivascular fibrosis (23 ± 2 vs.
30 ± 2%) and the occurrence of myocardial infarctions (12% vs. 36%) was significantly reduced. Track width, a measure of the animal's hind limb base of support
and representative of hypoxic brain damage, was also normalized as a result of molsidomine treatment (2.54 ± 0.04 vs. 2.91 ± 0.09 cm in controls). These findings
demonstrate that the NO donor molsidomine improves cardiac function, reduces neurological symptoms and enhances atherosclerotic plaque stability.
1. Introduction
Nitric oxide (NO) is involved in a wide range of physiological pro-
cesses in the cardiovascular system [1]. In blood vessels, NO is an im-
portant determinant of vascular tone, regulating blood pressure and
vascular compliance. Moreover, NO maintains vascular integrity by
inhibiting smooth muscle cell (SMC) proliferation, platelet aggregation
and leukocyte adhesion to the endothelium [1–3]. In the heart, NO
plays a major role in determining the resting vascular tone of coronary
resistance vessels [4,5] and is produced in cardiac SMC, where it reg-
ulates myocardial contractility [2,5]. Physical or biological injury to the
endothelium impairs the production and/or bioavailability of NO,
which may play a role in hypertension, reperfusion injury, athero-
sclerosis and myocardial depression [1,6,7].
In line with these findings, patients suffering from ischemic cardiac
failure and atherosclerosis might benefit from chronic treatment with
an exogenous NO donor. The NO donor molsidomine has the advantage
that it releases NO non-enzymatically, avoiding tolerance. Our group
and others have previously shown that molsidomine, which exerts its
effects through the metabolite 3-morpholinosydnonimine (SIN-1), fa-
voured cardiac function [8–12], decreased platelet aggregation
[11,13,14] and signs of oxidative stress and increased features of plaque
stability [15] in humans, as well as in animal models. Moreover, pa-
tients treated with molsidomine for over a year had significantly lower
plasma levels of soluble adhesion molecule ICAM-1, which may slow
down the progression of atherosclerosis [16]. However, the beneficial
effects of molsidomine are dose-dependent, since high amounts can
generate peroxynitrite, causing enhanced oxidative stress, thereby ag-
gravating atherosclerosis [17].
We recently described a novel atherosclerosis model, apolipoprotein
E-deficient mice with a mutation in the fibrillin-1 gene (ApoE-/-
Fbn1C1039G+/-), characterized by accelerated atherosclerosis, plaque
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rupture, myocardial infarction, cerebral hypoxia and sudden death
[18]. In these mice, the elastic fibers in the vessel wall are fragmented,
resulting in enhanced arterial stiffness and thereby mimicking vascular
aging [19]. As a result, ApoE-/-Fbn1C1039G+/- mice develop large and
highly unstable plaques with a phenotype similar to human plaques.
Moreover, these mice develop coronary artery plaques and left ven-
tricular hypertrophy, resulting in decreased cardiac function and
myocardial infarction. In the present study, we evaluated the effects of
chronic molsidomine treatment in ApoE-/-Fbn1C1039G+/- mice on
atherosclerotic plaque stability, cardiac function, neurological symp-
toms and sudden death.
2. Methods
2.1. Mice
Female ApoE-/-Fbn1C1039G+/- mice (n=70, 6 weeks of age) were fed
a Western-type diet (WD; TD88137, Harlan Teklad, Madison, WI) for up
to 25weeks. After 8 weeks of WD feeding, animals were divided into
two groups receiving either molsidomine via the drinking water (1mg/
kg body weight/day; n=34) or tap water (control; n= 36) until
25 weeks of WD. The animals were housed in a temperature-controlled
room with a 12-hour light/dark cycle with free access to water and
food. Mice were inspected daily for occurrence of sudden death. At the
end of the experiment, mice were anesthetized with sodium pento-
barbital (75mg/kg, i.p.) and blood samples were taken from the retro-
orbital plexus for plasma cholesterol analysis. Subsequently, animals
were euthanized with an overdose of sodium pentobarbital (250mg/kg,
i.p.). Total plasma cholesterol was analysed by means of a commercial
kit (Randox, Crumlin, UK). All experiments were approved by the
ethical committee of the University of Antwerp and were performed
according to the guidelines from Directive 2010/63/EU of the European
Parliament on the protection of animals used for scientific purposes.
2.2. Echocardiography
Transthoracic echocardiograms (ECGs) of ApoE-/-Fbn1C1039G+/-
mice were performed at the start (baseline, 8 weeks on WD) and after
12 weeks of molsidomine treatment. ECGs were performed on an-
esthetized mice (isoflurane, IsoFlo, Abbott) using a Toshiba diagnostic
ultrasound system (SSA-700A), equipped with a 15MHz transducer.
2.3. Blood pressure
Peripheral blood pressure was measured with a tail cuff (Coda™
High throughput, Kent Scientific, Torrington, CT). Mice were trained
for four weeks before the baseline measurement and every week
thereafter, until 12 weeks of molsidomine treatment, when a final
measurement was performed.
2.4. Motor coordination
Track width was analysed after 12 weeks of treatment as described
previously [20]. Briefly, ink was applied to the animals' hind paws and
the mice were required to walk on a strip of paper towards a dark goal
box. The median value of a minimum of 10 measurements per mouse
was used.
2.5. Histological evaluation
After euthanasia or sudden death, mice were dissected and aorta,
heart, spleen and kidneys were weighed (dry weight). Heart and ar-
teries were post-fixed in 4% formaldehyde (pH 7.4) for 24 h, processed
and embedded in paraffin. Histological analyses were performed on
serial cross sections (5 μm) of the brachiocephalic artery and proximal
ascending aorta. The percentage stenosis and the size of atherosclerotic
plaques and necrotic cores was measured on hematoxylin and eosin (H
&E) stained sections. The necrotic cores were defined as acellular/an-
uclear areas (negative for hematoxylin) with a 3000 μm2 threshold
implemented to avoid counting of very small H&E negative areas that
likely do not represent areas of necrosis. The presence of macro-
calcifications, identified as basophilic (dark purple) crystalline struc-
tures, was determined on H&E stained sections. The presence of 3-ni-
trotyrosine in plaques of the proximal ascending aorta was identified by
immunohistochemical staining with an anti-nitrotyrosine antibody (sc-
55,256, Santa cruz). Cellular composition of the atherosclerotic plaques
was analysed by immunohistochemistry using anti-mannose receptor
(macrophages, ab64693, Abcam) and anti-α-smooth muscle cell actin
(F3777, Sigma-Aldrich). Fibrous cap thickness was determined as the
median value of 10 measurements per atherosclerotic plaque on α-SMC
actin (F3777, Sigma-Aldrich) stained sections. Collagen content was
determined on Sirius red stained sections with light microscopy (total
collagen) and polarized light (type I collagen). Fibrous cap thickness
was determined as the median value of 10 measurements per athero-
sclerotic plaque on α-SMC actin (F3777, Sigma-Aldrich) stained sec-
tions. The ICAM-1 expression of the endothelial cells was measured via
immunohistochemical staining with an anti-vWF (PC054, The Binding
Site) and anti-ICAM-1 antibody (550287, BD Biosciences). The length of
CD31 positive cells along the luminal border was quantified in a com-
plete cross-section of the proximal ascending aorta and ICAM-1 posi-
tivity was expressed as percentage of CD31 positivity. Intraplaque
neovascularization and hemorrhages in the left common carotid artery
were examined on slides that were stained with anti-vWF (PC054, The
Binding Site) and anti-TER119 (550,565, BD Biosciences), respectively.
The occurrence of myocardial infarctions, coronary plaques and peri-
vascular fibrosis, measured as the perivascular collagen area divided by
the luminal area (PVCA/LA) of 10 coronary arteries per mouse, was
analysed on Masson's trichrome stained transversal sections (cut from
the middle of the heart to the apex). The myocardial infarctions were
defined as large fibrotic areas with infiltration of inflammatory cells. If
plaques were present in the coronary arteries, the plaque size and
percentage of stenosis were measured on Masson's trichrome stained
sections. All images were acquired with the Universal Grab 6.1. (IDL)
software (Exelis, Boulder, CO) using an Olympus BX40 microscope
(Tokyo, Japan). Images were quantified using Image J software (NIH).
2.6. Statistical analyses
Normally distributed data are expressed as mean ± SEM and non-
normally distributed variables are represented as median [min-max].
Statistical analyses were performed using SPSS software (version 24,
SPSS Inc., Chicago). Statistical tests are specified in the figure and table
legends. Histological data of the proximal ascending aorta and left
common carotid artery only include mice that survived the experiment.
Data on MI and coronary arteries include all mice. Differences were
considered significant at P < 0.05.
3. Results
Body weight and total plasma cholesterol was similar in treated and
control mice (Table 1). Survival improved slightly, albeit not sig-
nificantly, after molsidomine treatment (68% vs. 58% in controls,
Table 1). A marked decrease in kidney and spleen weight was observed
in the molsidomine-treated group, whereas lung weight remained equal
between both groups (Table 1).
3.1. Molsidomine improves atherosclerotic plaque stability
Molsidomine did not affect plaque size in the proximal ascending
aorta nor the degree of stenosis in ApoE-/-Fbn1C1039G+/- mice (Table 2,
Fig. S1). Furthermore, the NO donor had no effect on the size of the
necrotic core, the amount of macrophages, smooth muscle cells (SMCs),
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total collagen, type I collagen and endothelial ICAM-1 expression in the
plaque (Table 2, Fig. S1). Nonetheless, the fibrous cap was significantly
thicker in molsidomine-treated mice as compared to controls (Table 2,
Fig. S1). Molsidomine also induced the formation of intraplaque mac-
rocalcifications, as none of the control mice showed any signs of cal-
cified plaque regions as compared to 30% in the molsidomine-treated
mice (Fig. 1). The macrocalcifications were always located at the
medial side of the plaque. No signs of calcification were observed in the
fibrous cap. The calcified plaques showed a significantly higher type I
collagen content as compared to non-calcified plaques of molsidomine-
treated mice and controls (Table 2). Furthermore, the calcified plaque
area was negatively correlated with plaque size in the proximal as-
cending aorta (Pearson correlation; R square= 0.868, P= 0.021).
Importantly, there was no difference in the percentage of 3-nitrotyr-
osine, indicative of peroxynitrite-related oxidative stress, in plaques of
control and molsidomine-treated mice (Fig. S2). The occurrence of in-
traplaque neovascularization (control: 83%; molsidomine: 75%), the
number of microvessels (control: 4 [0–19]; molsidomine: 3 [0–19]) and
the occurrence of hemorrhages in the left common carotid artery
(control: 17%; molsidomine: 25%) was not affected by molsidomine
treatment.
3.2. Molsidomine reduces cardiac mass and improves cardiac function and
left ventricular hypertrophy
Systolic and diastolic peripheral blood pressure did not differ be-
tween the molsidomine and control group (Table 3). Echocardiography
of the heart revealed a significantly higher fractional shortening (FS)
and lower end diastolic diameter (EDD) and end systolic diameter
(ESD) in molsidomine-treated mice compared to controls (Fig. 2A–C).
Additionally, molsidomine significantly reduced heart mass as com-
pared to the ApoE-/-Fbn1C1039G+/- control mice (Fig. 2D). Cross-
sectional histological evaluation of the heart showed a decrease of one
third in the occurrence of myocardial infarctions after molsidomine
treatment (Table 3 and Fig. 2E). The infarcted area remained equal in
treated and control mice (Table 3). The occurrence of coronary artery
plaque and the percentage stenosis did not differ between molsidomine-
treated and control mice (Table 3). However, coronary perivascular
fibrosis was significantly reduced in the treatment group (Fig. 2F).
3.3. Molsidomine improves motor function of ApoE-/-Fbn1C1039G+/- mice
Track width measurements were previously validated as a reliable
marker for hypoxic brain damage in ApoE-/-Fbn1C1039G+/- mice [20].
Molsidomine was able to inhibit the increase in track width normally
observed in ApoE-/-Fbn1C1039G+/- mice fed a WD. Both the median and
maximum track width values were significantly lower after 12 weeks of
molsidomine treatment compared with control mice (Fig. 3A–B). Track
width was also positively correlated with plaque size in the proximal
ascending aorta (Fig. 3C).
4. Discussion
The present study confirms the beneficial effects of molsidomine in
the treatment of ischemic and left ventricular cardiac failure, as seen in
humans [8]. Moreover, molsidomine prevented a loss in motor function
and favoured atherosclerotic plaque stability. Molsidomine is a veno-
dilator that reduces the cardiac preload, thereby lowering cardiac
output, ventricular work and myocardial oxygen consumption [9].
Furthermore, it evokes a local dilatation of the coronary arteries, re-
ducing coronary artery stenosis and preventing cardiac ischemia [10].
ApoE-/-Fbn1C1039G+/- mice are characterized by the development of
pronounced atherosclerosis, which is caused by stiffening and in-
flammation of the arteries, as a result of elastin fragmentation in the
vessel wall [18,19]. These mice develop progressive cardiac failure,
coronary artery plaque, myocardial infarctions and hypoxic brain da-
mage, similar as seen in humans [18]. Therefore, they could benefit
from treatment with an exogenous NO donor. We chose for a chronic
treatment with a low dose of molsidomine (1mg/kg/day). It is very
important to select the most optimal dose, because high dosages can
generate peroxynitrite, causing enhanced oxidative stress, which may
lead to endothelial dysfunction [17]. This was also reported during
long-term treatment with other NO donors (nitroglycerin, isosorbide
mononitrate) [21]. Therefore, it is important to evaluate 3-nitrotyrosine
as a marker of peroxynitrite formation. In the current study, we could
not detect a difference between 3-nitrotyrosine in plaques of control
and molsidomine-treated mice. Thus, molsidomine at a dose of 1mg/
kg/day does not lead to oxidative stress-related side effects [15].
Importantly, molsidomine significantly improved cardiac function
Table 1
Characteristics of control and molsidomine-treated ApoE-/-Fbn1C1039G+/- mice.
Control Molsidomine
Survival (%) 21/36 (58%) 23/34 (68%)
Body weight (g) 23 ± 1 23 ± 1
Plasma cholesterol (mg/dl) 616 ± 57 621 ± 51
Organ weights (mg)
Spleen 174 ± 15 107 ± 9**
Lungs 229 ± 25 219 ± 18
Kidney 316 ± 23 242 ± 9**
Survival was evaluated using a Pearson's chi-square test. Body weight, plasma
cholesterol and organ weights are presented as mean ± SEM (n=13–18 per




Controla,b Molsidominea Molsidomine non calcifiedb Molsidomine calcifiedb
Vessel area (×103 μm2) 1379 ± 100 1284 ± 117 1399 ± 133 1015 ± 210
Plaque size (×103 μm2) 798 ± 67 792 ± 73 861 ± 83 630 ± 133
Stenosis (%) 58 ± 3 62 ± 2 62 ± 3 62 ± 4
Necrotic core (%) 8.6 ± 1.1 10.1 ± 1.4 10.9 ± 1.9 8.0 ± 1.5
Macrophages (%) 1.8 ± 0.3 2.7 ± 0.5 2.6 ± 0.6 3.0 ± 0.7
Total collagen (%) 39.8 ± 1.5 39.7 ± 1.2 38.2 ± 1.5 43.2 ± 1.4
Type I collagen (%) 3.4 ± 0.4 3.5 ± 0.4 2.8 ± 0.4 5.0 ± 0.5⁎,§§
Smooth muscle cells (%) 15.5 ± 1.1 14.2 ± 0.9 13.8 ± 1.3 15.3 ± 0.8
Fibrous cap thickness (μm) 8.1 ± 0.7 11.1 ± 1.2⁎ 10.5 ± 1.3 12.4 ± 2.6
ICAM-1 positive ECs (%) 94.4 ± 1.5 94.8 ± 1.4 94.5 ± 1.6 95.5 ± 2.8
Data from proximal ascending aorta, mean ± SEM, ECs= endothelial cells.
a n=20 per group. Independent samples t-test.
b Control: n= 20, molsidomine non calcified: n=14 and molsidomine calcified: n=6. One-way ANOVA, post hoc LSD.
⁎ P < 0.05 vs. control mice.
§§ P < 0.01 vs. molsidomine non calcified.
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(increased FS) and left ventricular hypertrophy (decreased EDD and
ESD) in ApoE-/-Fbn1C1039G+/- mice. Concomitant with these observa-
tions, a significant decrease in heart weight was observed, as well as a
clear decrease in the occurrence of myocardial infarctions. Molsidomine
did not significantly affect systolic or diastolic blood pressure, con-
sistent with previous observations in humans [8]. The observed influ-
ence of molsidomine treatment on the heart is probably related to its
hemodynamic effects, but we cannot exclude that also other pharma-
cological actions play a role. Further research, in which the response to
other NO donors is compared with molsidomine, is necessary to study
which mechanism of action contributes to the protective effects of
molsidomine on the heart.
Apart from its cardiac effects, molsidomine prevented an increase in
track width in ApoE-/-Fbn1C1039G+/- mice. We previously reported that
measuring track width in this mouse model is a reliable technique to
monitor hypoxic brain damage, as high track width values correspond
to the presence of more pyknotic neurons in the cerebral cortex [20].
Furthermore, track width correlated with plaque size in the proximal
ascending aorta [20], which we confirmed in the current study. As
molsidomine treatment resulted in lower track width values, it is likely
that it is able to prevent cerebral damage in ApoE-/-Fbn1C1039G+/- mice.
It is well-known that NO plays an important role in the regulation of
cerebral blood flow in normal and pathological conditions [22].
Therefore NO donors have been investigated as a therapeutic strategy
for preventing hypoxic brain damage. For instance, treatment with NO
donors prevented hypoxia-ischemia induced neurological damage in
rats [23,24] and a reduced brain infarct size was observed in several
animal models of stroke [25]. The trials involving the use of molsido-
mine are limited, but a recent observational study showed that after
subarachnoid haemorrhage, molsidomine treatment resulted in less
vasospasm-related infarctions and a better clinical outcome [26]. These
beneficial effects are not only attributed to the improved cerebral blood
flow, but also to other cellular and metabolic effects, such as the in-
hibition of neuronal apoptosis after ischemia [26]. Thus, the current
study further supports the finding that molsidomine treatment can
prevent hypoxic brain damage, but further clinical trials are needed to
confirm these results.
We also investigated whether molsidomine could have beneficial
effects on atherosclerosis. We did not observe a reduction in plaque size
nor degree of stenosis, confirming our previous observations [15]. Al-
though macrophage, SMC and total collagen content remained un-
altered, the NO donor significantly increased fibrous cap thickness, a
major determinant of tensile strength of the cap. NO is able to down-
regulate p53 and reduce the expression of pro-inflammatory cytokines
IL-1 and TNF-α, thereby decreasing apoptosis and inflammation [27].
In this way, SMC survival is favoured, leading to a thicker fibrous cap
and a more stable plaque phenotype. Moreover, molsidomine treatment
resulted in a significant increase in plaque macrocalcifications located
near the medial border. It is known that calcified coronary nodules are
a feature of acute coronary syndromes [28,29]. However, the type of
calcification observed in the present study does not resemble calcified
nodules since it is not eruptive and does not protrude into the lumen.
Furthermore, it is described that coronary artery calcification (CAC) is
associated with adverse cardiovascular events in humans, although it is
not correlated with plaque vulnerability [30–32]. Importantly, statin
therapy increases CAC, which is not related with an increased risk of
clinical complications [33–36]. This suggests that the increase in CAC
by statin therapy is plaque stabilizing rather than harmful. Thus, there
is still no consensus on the impact of calcification on plaque vulner-
ability and the overall prognosis of cardiovascular disease. In this re-
gard, it is important to differentiate between the presence of micro-
calcifications and macrocalcifications when evaluating the effect on
plaque stability. The formation of ‘spotty’ or microcalcifications is the
result of chronic plaque inflammation characterized by the presence of
pro-inflammatory cytokines such as IL-6 and TNF-α [37]. Under these
Fig. 1. Presence of plaque macrocalcifications. (A) H&E stained sections of the proximal ascending aorta showing the presence of a macrocalcification (dark purple)
as a result of molsidomine treatment (scale bar= 100 μm). (B) Percentage of mice showing plaque macrocalcifications in the proximal ascending aorta. Pearson's chi-
square test; **P < 0.01 vs. control mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 3
Blood pressure, MI and coronary artery plaque characteristics.
Control Molsidomine
Blood pressure (mm Hg)
Systolic BP 112 ± 7 111 ± 5
Diastolic BP 79 ± 7 77 ± 4
Pulse pressure 35 ± 1 33 ± 2
Myocardial infarction (MI)
Occurrence of MI 12/33 (36%) 4/33 (12%)⁎
Infarcted area (%) 1.8 ± 0.4 1.3 ± 0.5
Coronary plaque
Occurrence of coronary plaque 15/33 (45%) 14/33 (42%)
Stenosis (%) 58 ± 9 72 ± 8
Blood pressure is presented as mean ± SEM (n=13–18 per group) and ana-
lysed by Independent samples t-test. Occurrence of MI and coronary plaque
were evaluated using a Pearson's chi-square test. Infarcted area (in mice with
MI) and coronary stenosis (in mice with coronary plaque) are presented as
mean ± SEM and were analysed by an Independent samples t-test.
⁎ P < 0.05 vs. control mice.
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Fig. 2. Cardiac parameters of control and molsidomine-treated mice. (A–C) ApoE-/-Fbn1C1039G+/-mice treated with molsidomine (n=9) showed a significantly lower
end systolic diameter (ESD) and end diastolic diameter (EDD) as compared to controls (n= 9). Moreover, fractional shortening (FS) was significantly higher in the
molsidomine treatment group. Independent samples t-test; ⁎⁎P < 0.01 and ⁎⁎⁎P < 0.001. (D) Molsidomine treatment normalized heart weight of ApoE-/-
Fbn1C1039G+/- mice (n= 15 in both groups). Independent samples t-test; ⁎P < 0.05. (E) Histological images of Masson's trichrome stained hearts showing a myo-
cardial infarction (blue staining, arrow) in the right ventricle of the control-treated mouse. Scale bar= 500 μm. (F) Masson's trichrome staining of coronary arteries
indicated that perivascular fibrosis, measured as perivascular collagen area (PVCA) divided by the lumen area (LA), was significantly reduced in molsidomine-treated
mice as compared to controls. 2-way ANOVA; ⁎⁎P < 0.01. Scale bar= 100 μm. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
L. Roth, et al. Vascular Pharmacology 118–119 (2019) 106561
5
circumstances, remnants of apoptotic SMCs, which remain in the plaque
as matrix vesicles, will act as nucleating structures for calcification
[38,39]. These microcalcifications are associated with enhanced plaque
progression [32] and have the potential to increase the occurrence of
plaque rupture via the induction of biomechanical stress [32,40,41].
Considering the latter, the location in the plaque is also of great im-
portance, because only microcalcifications in the fibrous cap negatively
affect the mechanical stability, while calcifications found in the ne-
crotic core or at the medial border, as seen in the present study, do not
contribute to plaque instability [32,41]. In contrast to microcalcifica-
tions, macrocalcifications are considered plaque stabilizing, because
they are the result of a healing process that is able to separate the in-
flammatory plaque content from the vessel lumen [42]. These large
calcified areas are formed when the initial inflammation in the plaque is
resolved, leading to a tissue repair response and osteogenesis. There-
fore, large plaque calcifications have been associated with decreased
fibrous cap inflammation [43]. As bone formation is inhibited by
chronic inflammation, microcalcifications will not evolve into macro-
calcifications, unless the inflammatory status of the plaque decreases
[37]. NO has anti-inflammatory properties, which can explain the in-
crease in plaque macrocalcifications [27]. Molsidomine treatment was
introduced at a timepoint where advanced atherosclerotic plaques are
present in ApoE-/-Fbn1C1039G+/- mice, which is the ideal environment
for the development of microcalcifications, but the anti-inflammatory
effects of the therapy allowed osteogenesis to occur followed by the
formation of macrocalcifications. Moreover, we could detect a clear
increase in collagen type I in the calcified plaques, which is also a ty-
pical hallmark of a healing response after inflammation and further
stabilizes the atherosclerotic plaque. All these data indicate that mol-
sidomine treatment is able to favour plaque stability in advanced
atherosclerosis.
Interestingly, we also observed a lower spleen and kidney weight,
indicative of decreased inflammation. Other research groups have de-
monstrated that molsidomine was able to reduce kidney weight [12],
which was attributed to the anti-inflammatory and local dilating effects
of NO. [44] In addition, molsidomine modulates inflammation in var-
ious conditions such as muscular atrophy [45,46], wound healing [47]
and bacterial inflammation [48].
In conclusion, we demonstrated that administration of the NO donor
molsidomine improves heart function, reduces neurological signs and
enhances atherosclerotic plaque stability in a mouse model of vulner-
able plaque and spontaneous myocardial infarction. The effect of mol-
sidomine treatment on the phenotype of rupture-prone plaques in mice
is new and might offer opportunities to further investigate the use of
NO donors in atherosclerotic plaque stabilization and the prevention of
cardiac and cerebral ischemia.
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